Table 7.
Grading the evidence: secondary outcomes
| Quality assessment | № of patients | Absolute effect | Quality | Importance | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| № of studies | Study design | Risk of bias | Inconsistency | Indirectness | Imprecision | Other considerations | Indapamide | Bendroflumethiazide | (95% CI) | ||
| Systolic blood pressure (mmHg) (follow‐up: 1 year) | |||||||||||
| 2 | Randomized trials | Not serious | Not serious | Serious | Not serious | None | 1933 | 4297 | 0.94 (−1.45, 2.25) | ⨁⨁⨁◯ MODERATE | CRITICAL |
| Diastolic blood pressure (mmHg) (follow‐up: 1 year) | |||||||||||
| 3 | Randomized trials | Not serious | Not serious | Serious | Not serious | None | 1933 | 4355 | 0.88 (−0.19, 1.95) | ⨁⨁⨁◯ MODERATE | CRITICAL |
| Systolic blood pressure (mmHg) (follow‐up: range 12–24 weeks) | |||||||||||
| 3 | Randomized trials | Serious | Not serious | Not serious | Serious | None | 29 | 27 | −0.26 (−0.79, 0.27) | ⨁⨁◯◯ LOW | IMPORTANT |
| Diastolic blood pressure (mmHg) (follow‐up: range 12–24 weeks) | |||||||||||
| 3 | Randomized trials | Serious | Not serious | Not serious | Serious | None | 29 | 27 | −0.40 (−0.93, 0.14) | ⨁⨁◯◯ LOW | IMPORTANT |
CI, confidence interval